Real-world Data on the Efficacy and Safety of Ixazomib-based Therapy in Multiple Myeloma: A Single-center Study in China
Authors Ding K, Yu H, Shao YY, Li LY, Wang CM, Song J, Li LJ, Fu R
Received 14 May 2020
Accepted for publication 1 August 2020
Published 23 September 2020 Volume 2020:12 Pages 8935—8941
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Sanjeev Srivastava
Kai Ding ,* Hong Yu ,* Yuan-Yuan Shao, Li-Yan Li, Chao-Meng Wang, Jia Song, Li-Juan Li, Rong Fu
Department of Hematology, Tianjin Medical University General Hospital, Tianjin 300052, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Rong Fu Tel +86-18622008752
Objective: To assess the short-term efficacy and safety of ixazomib in Chinese multiple myeloma (MM) patients in the real world.
Methods: Fifty-nine MM patients who received at least one cycle of ixazomib-based therapy between 1 June 2018 and 30 September 2019 were retrospectively analyzed in Tianjin Medical University General Hospital. Thirteen newly diagnosed MM (NDMM), 13 refractory/relapsed MM (RRMM) and 33 continuous therapy (27 bortezomib peripheral neuritis (PN) intolerant and six maintenance therapy) MM patients were included. The indicated overall response rate (ORR), time to overall response (TOR), and adverse events (AEs) were investigated.
Results: The ORR in NDMM was 76.9%, with one complete response (CR), five very good partial response (VGPR), four partial response (PR), median PFS, and TOR were 122 (66– 272) days and 49 (22– 108) days. The ORR in RRMM was 46.2%, with one CR, two VGPR, three PR, median PFS, and TOR were 79 (28– 169) days and 59 (23– 88) days. The ORR in continuous therapy MM patients was 100%, with nine stringent CR, 15 CR, six VGPR and three PR, median TOR was 75 (25– 141) days. There were no significant differences regarding ORR between patients with cytogenetic high risk and standard risk in three subgroups (all P> 0.05). The most frequent hematological AEs were anemia (13.6%) and thrombocytopenia (10.2%). The most common nonhematological AEs were PN (25.0%) and diarrhea (13.6%).
Conclusion: The real-world data demonstrated that ixazomib-based therapy was generally effective and safe in the short term for MM patients.
Keywords: multiple myeloma, ixazomib, real world, overall response rate, adverse events
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]